Atopic Dermatitis/Atopic Eczema | Unmet Need | Pediatric | US/EU | 2019
The management of pediatric patients with moderate to severe atopic dermatitis (AD) is poised for transformation. Sanofi/Regeneron’s Dupixent, on the heels of a positive Phase III study in adolescent patients, appears set to gain expanded approval in this population beginning in 2019, and the late-stage pipeline features compelling programs, including Pfizer’s abrocitinib and AbbVie’s upadacitinib. Pediatric patients comprise a sizable percentage of the AD population, and clinicians appear to manage them with a risk tolerance that is lower than accepted in adult patients. We will assess the commercial opportunity in the pediatric, topical-refractory, moderate to severe AD space through a comprehensive look at the key efficacy, safety, and delivery attributes driving prescribing choice; the gaps in treatment left by current therapies; and the interplay of clinical and nonclinical attributes in determining the appeal of potential AD products in the pediatric population.
QUESTIONS ANSWERED
- How do surveyed dermatologists rate the performance of current therapies (e.g., Sanofi/Regeneron’s Dupixent, cyclosporine) on attributes including effect on eczema, effect on itch, safety/tolerability, delivery, and nonclinical factors?
- What are the most compelling unmet treatment needs that would drive positive differentiation in this arena (e.g., fast onset of action)? How well poised are pipeline agents (e.g., Pfizer’s abrocitinib, AbbVie’s upadacitinib) to capitalize on them?
- What trade-offs between clinical attributes and price will clinicians accept when considering whether to prescribe a hypothetical AD target product profile?
Markets covered: United States, United Kingdom, France, Germany
Primary research: Survey of 60 U.S. and 30 European dermatologists treating pediatric patients
Key companies: Sanofi, Regeneron, Pfizer, AbbVie, LEO Pharma, Eli Lilly, Incyte, Vanda, Novartis, Galderma, Dermira
Key drugs: Dupixent, cyclosporine, methotrexate, azathioprine, mycophenolate, oral prednisone
KEY METRICS INCLUDED
- Target Product Profile (TPP) simulator based on conjoint analysis methodology
- Stated versus derived importance of product attributes on prescribing behavior
- Assessment of current drug performance against treatment drivers and goals
- Physician perceptions of unmet needs in the indication and related indications
- Analysis of remaining
- Drug development opportunities
PRODUCT DESCRIPTION
Unmet Need supports clinical development decisions by identifying key attributes and assessing areas of unmet need for a specific disease or subpopulation. Based on surveys with U.S. and European physicians, this report provides insight into key treatment drivers and goals, the performance of current therapies, and the remaining commercial opportunities. Two market scenarios are profiled in detail by DRG experts, and additional customized market scenarios can be evaluated with the corresponding TPP simulator.
